Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02097277 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 219
- Enrollment target
NCT02097277 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 219 participants.
The verdict
NCT02097277, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 219 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults with type-2 diabetes.
Interventions
- BIOLOGICAL BMS-986036
- BIOLOGICAL Placebo (Matching with BMS-986036)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2014-04-15 |
| Est. Completion | 2016-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02097277
The ClinicalTrials.gov registry entry for NCT02097277 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986036 is the first listed.
NCT02097277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02097277 about?
NCT02097277 is a clinical study titled "A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes". The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults with type-2 diabetes.
What is the current status of trial NCT02097277?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 219 participants. The study started on 2014-04-15. Estimated completion is 2016-05-17.
What interventions are being tested in trial NCT02097277?
The interventions under investigation include: BMS-986036 (BIOLOGICAL), Placebo (Matching with BMS-986036) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02097277?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.